This listing of claims will replace all prior versions, and listings, of claims in the application.

Listing of Claims:

1. (***Currently Amended***) A solid dispersion comprising a poorly soluble bioactive compound dispersed in a polymer matrix that comprises a first polymer **comprising a copolymer of vinylpyrrolidone and vinylacetate** ~~that allows a homogenous or molecular dispersion of the bioactive compound in the polymer matrix~~ and a second polymer that has a dissolution profile associated with the creation of a micro-environment enhancing the dissolution of the bioactive compound in an aqueous environment, wherein said first polymer and said second polymer are present in a ratio of about 70:30 to about 80:20.

2. (***Previously Presented***) The solid dispersion according to claim 1 characterized in that the polymer matrix comprises a polymer having a stabilizing effect on the bioactive compound in solution.

3. (***Canceled***)

4. (***Previously Presented***) The solid dispersion according to claim 1 wherein the polymer allowing enhanced dissolution of the bioactive compound in an aqueous environment is a cationic polymer based on dimethylaminoethyl methacrylate and neutral methacrylic ester.

5. (***Previously Presented***) The solid dispersion according to claim 1 wherein the polymer allowing enhanced dissolution of the bioactive compound in an aqueous environment is hydroxyl-propyl methyl cellulose.

6. (***Currently Amended***) The solid dispersion according to claim 1 wherein the polymer matrix comprises a cationic polymer based on dimethylaminoethyl methacrylate and neutral methacrylic esters and **said first polymer** ~~a copolymer of vinylpyrrolidone and vinylacetate~~.

7. (***Canceled***)

8. (***Canceled***)

9. (***Previously Presented***) The solid dispersion according to claim 1 enhancing the bioavailability of an orally administered bioactive compound.

10. (***Previously Presented***) The solid dispersion according to claim 1 wherein the bioactive compound is a class II drug in the Biopharmaceutical Classification System.

11. (***Previously Presented***) The solid dispersion according to claim 1 wherein the bioactive compound is a class IV drug in the Biopharmaceutical Classification System.

12. (***Previously Presented***) The solid dispersion according to claim 1 wherein the aqueous environment is a gastro-intestinal fluid.

13. (***Previously Presented***) The solid dispersion according to claim 12 wherein the aqueous environment is a gastric fluid.

14. (***Previously Presented***) The solid dispersion according to claim 1 prepared by extrusion.

15. (***Previously Presented***) The solid dispersion according to claim 1 prepared by spray-drying.

16. (*New*) A solid dispersion comprising a poorly soluble bioactive compound dispersed in a polymer matrix that comprises a first polymer that allows a homogenous or molecular dispersion of the bioactive compound in the polymer matrix and a second polymer that has a dissolution profile associated with the creation of a micro-environment enhancing the dissolution of the bioactive compound in an aqueous environment, wherein said first polymer and said second polymer are present in a ratio of about 70:30.

17. (*New*) The solid dispersion according to claim 1 characterized in that the polymer matrix comprises a polymer having a stabilizing effect on the bioactive compound in solution.

18. (*New*) The solid dispersion according to claim 1 wherein the polymer allowing a homogenous dispersion is a copolymer of vinylpyrrolidone and vinylacetate.

19. (*New*) The solid dispersion according to claim 1 wherein the polymer allowing enhanced dissolution of the bioactive compound in an aqueous environment is a cationic polymer based on dimethylaminoethyl methacrylate and neutral methacrylic ester.

20. (*New*) The solid dispersion according to claim 1 wherein the polymer allowing enhanced dissolution of the bioactive compound in an aqueous environment is hydroxyl-propyl methyl cellulose.

21. (*New*) The solid dispersion according to claim 1 wherein the polymer matrix comprises a cationic polymer based on dimethylaminoethyl methacrylate and neutral methacrylic esters and a copolymer of vinylpyrrolidone and vinylacetate.

22. (*New*) The solid dispersion according to claim 1 wherein the polymer matrix comprises hydroxyl-propyl methyl cellulose and a copolymer of vinylpyrrolidone and vinylacetate.

23. (*New*) The solid dispersion according to claim 1 enhancing the bioavailability of an orally administered bioactive compound.

24. (*New*) The solid dispersion according to claim 1 wherein the bioactive compound is a class II drug in the Biopharmaceutical Classification System.

25. (***New***) The solid dispersion according to claim 1 wherein the bioactive compound is a class IV drug in the Biopharmaceutical Classification System.

26. (***New***) The solid dispersion according to claim 1 wherein the aqueous environment is a gastro-intestinal fluid.

27. (***New***) The solid dispersion according to claim 12 wherein the aqueous environment is a gastric fluid.

28. (***New***) The solid dispersion according to claim 1 prepared by extrusion.

29. (***New***) The solid dispersion according to claim 1 prepared by spray-drying.